Major Players profiled in the HIV Market report incorporate: Bristol-Myers Squibb Company, ViiV
Healthcare (Pfizer Inc.) and GlaxoSmithKline plc, Gilead Sciences Inc., Boehringer Ingelheim (C.H.
Boehringer Sohn AG & Ko. KG), F. Hoffmann-La Roche AG, Abbott Laboratories Inc., Janssen
Therapeutics, Merck & Co. Inc., Cipla Limited.
Latest Industry News
1 Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously
announced sale of its HIV R&D portfolio to ViiV Healthcare, which includes a number of programs at
different stages of discovery, preclinical and clinical development. Bristol-Myers Squibb received from
ViiV Healthcare a payment of $350 million in connection with the closing. Under the terms of the
transaction agreements, Bristol-Myers Squibb will also receive from ViiV Healthcare potential
development and regulatory milestone payments of up to $518 million for the clinical assets, and up to
$587 million for the discovery and pre-clinical programs. If and when products are approved and
commercialized, ViiV Healthcare will pay tiered royalties. Additionally, ViiV Healthcare will pay sales-
based milestone payments of up to $750 million for each of the clinical assets and up to $700 million for
each of the discovery and pre-clinical programs.
2 Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new
data from the company’s HIV clinical development program are scheduled to be presented at the
Conference on Retroviruses and Opportunistic Infections (CROI 2019) taking place March 4-7, 2019 in
Seattle, WA. Presentations include an integrated efficacy analysis of data from the Phase 3 DRIVE-
FORWARD and DRIVE-AHEAD trials that evaluated DELSTRIGO (doravirine/lamivudine/tenofovir
disoproxil fumarate) and PIFELTRO™ (doravirine) in treatment-naïve adults; data on the safety of
ISENTRESS® exposure in pregnancy; and findings from a clinical pharmacokinetic (PK) study of MK-8591,
a novel investigational nucleoside reverse transcriptase translocation inhibitor.
Purchase this report online with 50 Pages, List of Tables & Figures and in-depth Table of Contents on
“Global HIV Market Report 2019” @ https://www.businessindustryreports.com/buy-
now/162963/single .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of HIV in these regions, from 2014 to 2023 (forecast), covering: North America,
Europe, Asia Pacific, Middle East & Africa and South America.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation
(Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost
Analysis, and Conclusion.
Report contents include
1 Analysis of the HIV Market including revenues, future growth, market outlook
2 Historical data and forecast